跳至主要内容
临床试验/NL-OMON22227
NL-OMON22227尚未招募不适用

Potential screening participants’ and physicians’ preferences on optimizations of population based colorectal cancer screening, a discrete choice experiment

Radboudumc0 个研究点目标入组 600 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
Radboudumc
入组人数
600

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • -Randomly selected from the municipal database of Nijmegen
  • -Practicing gastroenterologist, fellows or general practitioner in the Netherlands

排除标准

  • -Subject is illiterate or unable to provide informed consent

研究者

发起方
Radboudumc

相似试验

已完成
不适用
PressUre uLCers: Effectiveness of Risk assessment tools. A randomised controlled trial (the ULCER Trial)
ACTRN12608000541303Joan Webster1,070
招募中
不适用
Experiences of the use of the English version of an iPad application Aid for decision-making in occupation choice ,(ADOC-E), for shared decision making around goal setting in rehabilitation: a qualitative descriptive studyPhysical rehabilitationPhysical Medicine / Rehabilitation - Occupational therapyPhysical Medicine / Rehabilitation - Other physical medicine / rehabilitationPhysical Medicine / Rehabilitation - PhysiotherapyPhysical Medicine / Rehabilitation - Speech therapyInjuries and Accidents - Other injuries and accidents
ACTRN12620001328965niversity of Otago18
已完成
不适用
Pilot randomised controlled trial of electronic screening and brief intervention (e-SBI) to increase uptake of referral for specialist care among hospital outpatients with possible alcohol dependenceAlcohol dependence
ACTRN12612000919819Associate Professor Kypros Kypri128
招募中
不适用
Screening participant and health service impact of population-based breast density notification in Australia: a randomised controlled trial in BreastScreen QueenslandBreast cancer
ACTRN12623000001695The University of Sydney2,856
已完成
不适用
Health testing with all subjects who participated in any phase I clinical study and received at least one dose of HTL0018318/AGN-242071 to date.General Health10019654
NL-OMON48060Heptares Therapeutics Ltd.170